TERMINATED

Conversational Agents to Improve HPV Vaccine Acceptance in Primary Care (ECA-HPV)- Clinical Trial

Talk to us

Conditions

Human Papilloma VirusCancer PreventionVaccination PromotionVaccination AttitudesVaccination Completion

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The objective of this study is to assess the use of and satisfaction with the ECA-HPV intervention over a 16-month period, its ability to increase HPV vaccination, and the comparative effectiveness of clinic notification and adolescent ECA components on these factors.

Official Title

Conversational Agents to Improve HPV Vaccine Acceptance in Primary Care

Quick Facts

Study Start:2024-11-13
Study Completion:2025-04-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:TERMINATED

Study ID

NCT06367699

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:8 Years to 12 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD
Inclusion CriteriaExclusion Criteria
  1. 1. Speaks English fluently
  2. 2. Able to independently consent
  3. 3. Has adequate corrected vision to use the ECA-HPV system (based on their ability to go through the consent form)
  4. 4. Has adequate hearing to use the ECA-HPV system (based on their ability to hear the research staff member conducting the consent process)
  5. 5. Has a smartphone that is able to support the ECA-HPV app
  6. 1. Is between the ages of 9-12 at the time of the index (first) well child visit
  7. 2. Has received either 1 or none of the HPV vaccine series
  8. 3. Speaks English fluently
  9. 4. Able to independently assent
  10. 5. Has adequate corrected vision to use the ECA-HPV system
  11. 6. Has adequate hearing to use the ECA-HPV system
  12. 7. Has a smartphone or has access to parent/guardian's smartphone (that is able to support the ECA-HPV app)
  13. 8. Has an upcoming well child visit at Boston Medical Center
  14. 1. Is not able to use the ECA-HPV system
  15. 2. Has already participated in the study before
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Principal Investigator

Michael Paasche-Orlow, MD, MPH
PRINCIPAL_INVESTIGATOR
Tufts Medical Center

Study Locations (Sites)

Boston Medical Center
Boston, Massachusetts, 02118
United States

Collaborators and Investigators

Sponsor: Tufts Medical Center

  • Michael Paasche-Orlow, MD, MPH, PRINCIPAL_INVESTIGATOR, Tufts Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-11-13
Study Completion Date2025-04-01

Study Record Updates

Study Start Date2024-11-13
Study Completion Date2025-04-01

Terms related to this study

Keywords Provided by Researchers

  • Human Papilloma Virus
  • Cancer Prevention
  • Vaccination Promotion
  • Vaccination Attitudes
  • Vaccination Completion

Additional Relevant MeSH Terms

  • Human Papilloma Virus